Background Patient engagement in clinical practice guideline (CPG) development is recommended by multiple institutions and instruments measuring guideline quality. Approaches to engaging patients, however, vary between oversight organizations, quality tools and guideline developers.
Background
International guideline standards describe patient engagement as a key element of highquality evidence-based clinical practice guidelines (CPGs). The Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument for evaluating CPGs requires that guideline developers seek the views of the target population, 1 the World Health Organization (WHO) recommends stakeholder involvement if 'feasible and efficient', 2 and other bodies recommend inclusion of patients on guideline development groups (GDGs) [3] [4] [5] ( Table 1) . Rationales for patient engagement in CPGs include recognizing patients as experts with important contributions, empowering consumers in well-informed healthcare decisions 'A guideline development panel should include diverse and relevant stakeholders, such as health professionals, methodologists, experts on a topic and patients or other healthcare consumers' IOM 5 Standard 3.1: 'The GDG should be multidisciplinary and balanced, comprising a variety of methodological experts and clinicians, and populations expected to be affected by the CPG.' Standard 3.2: 'Patient and public involvement should be facilitated by including (at least at the time of clinical question formulation and draft CPG review) a current or former patient and a patient advocate or patient/consumer organization representative in the GDG'. Standard 3.3: 'Strategies to increase effective participation of patient and consumer representatives, including training in appraisal of evidence, should be adopted by GDGs'. Standard 7.1: 'External reviewers should comprise a full spectrum of relevant stakeholders, including scientific and clinical experts, organizations (e.g. health care, specialty societies), agencies (e.g. federal government), patients and representatives of the public'. Standard 7.4: 'A draft of the CPG at the external review stage or immediately following it (i.e. prior to the final draft) should be made available to the general public for comment. Patient engagement guideline framework, M J Armstrong et al.
and respecting the rights of citizens in healthcare policy; goals include the development of more patient-centred and trustworthy guidelines that lead to improved implementation and quality of care. 6 While the tendency to include patients' views is clear, guidance on 'who', 'how' and 'when' varies with no evidence guiding best practice. For the 'who', strategies include engaging patients, caregivers/family members, advocates, and/or consumers, with different reasons these approaches may be preferable. Various approaches also exist for recruiting representatives who will express not only their own views but also those of others. In this Viewpoint, however, we focus on a framework outlining possibilities for the 'how' and the 'when' of patient engagement in CPGs. We use the term 'patient' to refer to all of the lay stakeholders filling this role, consistent with other frameworks. 7 In considering the 'how' of patient involvement, the Guidelines International Network (G-I-N) PUBLIC Toolkit describes strategies and outlines three potential approaches: (1) consultation, where patient preferences are collected through direct consultation or review of published literature, (2) participation, where patients participate in GDGs, and (3) communication, where information is provided to the public through laytargeted materials. 6 As examples of soliciting views and preferences of target populations, AGREE II lists literature reviews of published preferences, formal consultations/interviews, participation on GDGs and external review. 1 No research exists regarding best practices for the 'how' of obtaining patients' views or whether single strategies are sufficient. Additionally, there is variation in views regarding the 'when' of soliciting patient preferences. The Institute of Medicine (IOM) standards require that patients participate in GDGs, but qualify this by saying that GDG patient participation should be 'at least at the time of clinical question formulation and draft CPG review'. 5 AGREE II does not specify the times for solicitation of patient views. 1 A review found that patients are most commonly engaged in CPG development during knowledge synthesis, recommendation development and draft revision, 8 but patients may also be engaged in CPG development decisions (e.g. scope, GDG participants) 8 or creation of lay-targeted guideline materials. 4, 8, 9 Most discussions of patient engagement relate to involvement at the level of the individual guideline rather than development steps occurring at developer or committee levels. Given that optimal approaches for the methods and timing of patient engagement in CPG development are unknown, having a framework outlining guideline development and potential patient contributions at each step is critical. We thus propose a framework for patient engagement in guideline development ( Table 2 ) that can facilitate discussion of continuous patient engagement (i.e., at developer, committee and individual guideline levels) and allow guideline developers and researchers to identify steps at which patients are engaged and methods by which this can be achieved. This ten-step framework resulted from collaboration between the developer of the framework for continuous patient engagement in comparative effectiveness research 10 and a guideline methodologist researching patient engagement in CPGs. Iterative revisions resulted from suggestions from others with guideline expertise. The framework includes common guideline development steps and optional (non-exhaustive) methods for patient engagement at each step based on a review of published literature and pragmatic experience.
Framework
There are opportunities for patient engagement throughout the guideline process. In this proposed ten-step framework (Table 2) , we include steps typically performed at the developer or committee level (Steps 1-3, 9, 10) and those which relate to specific guidelines (Step 4-8).
As a first step (Step 1), patients can identify important guideline topics. Determining priority topics is one method for patient engagement identified by AGREE II. 1 Patient engagement guideline framework, M J Armstrong et al.
patients, however, is unclear. Active solicitation of guideline topics through community meetings, focus groups or contacting advocacy organizations may be more likely to successfully engage patients. Given limited resources, however, guideline developers are unable to accept every nomination. Engaging patients in prioritizing nominated topics and selecting topics to proceed to guideline development (Step 2) can ensure that guideline developers are addressing target population needs. While engagement of this type is not widely described, the National Institute for Clinical Excellence (NICE) consults the public on whether particular technologies should be reviewed prior to initiating guideline development. Once topics are accepted for development, patients can be involved in key process decisions including proposing and vetting GDG members (Step 3), framing the question (Step 4) and developing the research plan (Step 5). It is likely that if patient engagement impacts ultimate implementation success, engaging patients at early stages will be particularly important. The challenge of conflicts of interest (COIs) in guideline development is subject to on-going debates with implications for guideline bias and end-user trust. Assessing and managing COIs are thus critical parts of guideline development. 1, 3, 5 Patients engaged in assessing COIs could provide a unique and novel voice in this process. Patients could also contribute meaningfully to developing guideline questions (Step 4). While limited research exists regarding the impact of patient engagement on CPGs, a descriptive study found that patient engagement resulted in the introduction of a new guideline subtopic. 9 As part of question development, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group suggests that GDGs rate the significance of patientimportant outcomes, 11 a process that is clearly more meaningful with patients involved. At the research plan step (Step 5), patients' input can help determine key elements to consider in the analytic framework (e.g. harms), suggest whether there are proxies for framework concepts and identify special populations of interest (e.g. those with comorbidities). This can be accomplished through reviewing literature regarding patient preferences and direct engagement through patient GDG participation, but it is common for guideline developers (e.g. United States Preventive Services Task Force [USPSTF], NICE) to also seek patient involvement at this stage through posting of research plans for public comment.
The degree to which patients should be engaged in the completion of the systematic review (Step 6) is debated, with some guideline developers describing active patient participation 8 but others describing this as a barrier to successful patient engagement. 4, 8, 12 NICE identifies the ability to understand scientific articles (with training) as part of the minimum skill set for patient and caregiver GDG participants 4 and organizations like Consumers United for Evidence-based Healthcare (CUE) can provide consumers with training on critical appraisal and evidence-based medicine. However, requiring patient GDG members to participate in formally grading systematic review evidence may limit individuals' interest in participation (based on time requirements, skill set) and result in underrepresentation of less educated populations whose views and opinions are important to solicit. Approaches to this include having GDG patient representatives who do not participate in the systematic review but contribute at other steps or providing training for GDG members. Posting of draft evidence summaries and conclusions for public comment feedback, particularly for face validity and meaningfulness, is another route for engaging patients at this step of the guideline process and is an approach already utilized by some developers (e.g. USPSTF).
There is near-universal agreement that guideline developers need to engage patients in recommendation development (Step 7). The patient role in recommendation development is broad (Table 2) , with contributions particularly relating to providing insight into how patient preferences inform recommendations and ensuring that recommendations facilitate patient-centred care. Given patients' key role in recommendation development, guideline developers may use multiple strategies for patient engagement particularly at this step, including direct engagement through GDGs and obtaining diverse opinions through posting of draft recommendations for public comment.
A key guideline step in which patients are commonly engaged is that of dissemination and implementation (Step 8 Patient engagement guideline framework, M J Armstrong et al.
guidelines with terminology and language that patients use and value such that less rephrasing is required for implementation and clinician use. Patients clearly play an important role in developing lay language guideline versions and other public products, 4, 8, 9 but their engagement at this step should not be limited to this one contribution. Some organizations accept patient endorsement of guidelines to demonstrate patient support for recommendations. Positive endorsement may rely on patient engagement at prior steps: articles describe guideline endorsement after successful patient engagement 9 and also failure of endorsement when an engaged patient participant felt that his contribution was not valued. 12 Engaging patients and patient advocacy groups in dissemination could also be a key avenue for improving guideline awareness and implementation.
Quality CPGs have plans for currency reviews and updates 1,3,5 (Step 9). As with topic nomination, patients can assist in this step by helping determine whether and when guidelines require update, particularly if there is a social or public reason for update apart from new evidence. Select guideline developers have processes for this in place, including the USPSTF, which allows the public to submit requests for topic reconsideration, and NICE, which invites review consultations when guideline update decisions are being made. Finally, guideline developers should have mechanisms in place to evaluate the success of their patient engagement strategies (Step 10). In this setting, patients can help determine whether their contributions were meaningful and strategies for improved future participation.
Barriers
While there are opportunities for patient involvement at each guideline development stage, barriers exist. A commonly cited barrier is the ability of patients to understand medical terminology and participate meaningfully in assessing research quality. 3, 4, 8, 12, 13 
Conclusions
Opportunities exist for patient engagement throughout guideline development, both in steps occurring at the developer level and steps that are guideline project specific. Patient engagement at each step has different purposes, mechanisms, advantages and disadvantages, and implications for resource utilization. Guideline developers need to thoughtfully consider patient engagement at each step; specific goals may dictate types of engagement utilized. Engaging patients through multiple mechanisms -for example, GDG participation and public comment -has advantages and may be a particularly important strategy for addressing barriers such as GDG members representing only select views. Using multiple engagement strategies (e.g. literature review, direct representation on GDGs and public comment) allows for increased representation of patient views but also allows developers to prioritize limited resources for certain steps and respect patients' time and work capacity by actively engaging them at targeted steps while using alternate strategies (e.g. systematic literature reviews of patient preferences, public comment) for other steps. For certain strategies, additional training may be needed for both patients and the panels that are engaging them. Resource availability, time sensitivity and disease-specific considerations (e.g. cognitive impairment) may influence when and how guideline developers engage patients. It remains uncertain whether continuous patient engagement at each of the ten steps has superior outcomes vs. engagement only at select steps. It is hoped that engaging patients will enhance the validity and usefulness of published guidelines. The result will be CPGs that are more meaningful to patients, thus improving clinical practice, decision making and patientrelevant outcomes.
